FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.
What happened
FDA reviewed the company’s website at https://www.trygenesis.com in December 2025 and observed that it offers compounded semaglutide and tirzepatide drug products. FDA says the pictured labels show “Genesis” in a way that suggests Genesis is the compounder when it is not, and the site claims the products contain the same active ingredient as Ozempic, Wegovy, or Mounjaro. FDA calls these claims false or misleading and the products misbranded.
What FDA found
FDA says the website labels show “Genesis” in a way that suggests Genesis is the compounder of the drugs when it is not, so the labeling is false or misleading.
FDCA §502(a) [21 U.S.C. §352(a)]; 21 CFR §201.1(h)(2)FDA says the website’s advertising and promotion are false or misleading for the same reason.
FDCA §502(bb) [21 U.S.C. §352(bb)]FDA says the claim “Contains the same active ingredient as Ozempic® and Wegovy®” implies FDA approval or evaluation that the compounded products do not have.
FDCA §502(a), §502(bb) [21 U.S.C. §§352(a), 352(bb)]FDA says the claim “Same active ingredient as Mounjaro®” implies FDA approval or evaluation that the compounded products do not have.
FDCA §502(a), §502(bb) [21 U.S.C. §§352(a), 352(bb)]FDA says the misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA §301(a) [21 U.S.C. §331(a)]FDA says receiving misbranded drugs in interstate commerce and delivering them is also prohibited.
FDCA §301(c) [21 U.S.C. §331(c)]
What FDA wants
Within 15 working days of receipt, Genesis must send a written response to FDA’s Office of Compounding Quality and Compliance describing steps taken to address the violations and prevent recurrence. FDA asks Genesis to identify the entities that produce the compounded products, provide sample labeling, and address the basis for the website claims or show they were modified or removed.
Who should pay attention
- telehealth companies marketing compounded semaglutide or tirzepatide
- compounding pharmacies whose products are sold through other websites
- companies whose names appear on drug labels as manufacturer or compounder
This is a summary. Read the original letter on fda.gov.